Small Molecule-Mediated Nrf2 Activation as a Neuroprotective Approach in Multiple Sclerosis

Authors: Borole, Arnav; Boguszewski, Kevin; Furmanski, Philip; Suh, Nanjoo

Source journal: Drug development research (2026-12-01)

DOI: 10.1002/ddr.70406

Abstract

Multiple sclerosis is a chronic inflammatory autoimmune disease resulting in progressive demyelination of the central nervous system, leading to symptoms such as motor discoordination, cognitive deficits, and ocular dysfunction. Oxidative stress is a crucial component in the pathogenesis of multiple sclerosis, with reactive oxygen species contributing to myelin destruction, neuronal injury, and disruption of the blood-brain barrier resulting in symptom progression. For this reason, reducing oxidative stress has gained attention as a promising mechanism of disease control. Nuclear factor erythroid-2-related factor-2 (Nrf2) is a master regulator of the cellular antioxidant and anti-inflammatory response throughout the body, including the central nervous system. Nrf2 functions as a transcription factor to activate the expression of genes involved in detoxification and antioxidant defense, thus playing a critical role in limiting neuronal oxidative damage resulting from multiple sclerosis. Since no curative treatments are currently available for multiple sclerosis, recognizing potential new drugs that target earlier stages of the disease may be a viable strategy to intervene in disease progression and improve quality of life for the patient. This review explores how Nrf2 is a promising target for intervention in multiple sclerosis and that many Nrf2 activators exhibit robust efficacy, highlighting their potential as novel agents for multiple sclerosis treatment.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.